Orum Therapeutics is a public biotechnology company pioneering the development of Degrader-Antibody Conjugates (DACs). Our mission is to cure cancer and other serious diseases by combining the precise tumor-targeting power of antibodies with the potent intracellular destruction capability of targeted protein degraders(TPD).

Orum Therapeutics, Inc. is incorporated in South Korea.

We operate as a global biotech to leverage the best talent and infrastructure in both regions:

• HQ and Lab: Daejeon, South Korea

• US Lab : Lexington, Massachusetts, USA

Unlike traditional Targeted Protein Degraders (TPDs) that can affect healthy cells, or traditional Antibody-Drug Conjugates (ADCs) that use cytotoxic payloads, our TPD² (Dual-Precision Targeted Protein Degradation) approach uses antibodies to deliver novel protein degrader payloads directly into target cells. This "dual precision" improves the therapeutic window, making drugs potentially safer and more effective. Our most advanced platform leverages GSPT1 molecular glues as payloads.

While both use antibodies to target cancer cells, the difference lies in the payload (the "warhead"):

• Traditional ADC: Uses a chemotherapy toxin to kill the cell.

• DAC: Uses a protein degrader (molecular glue) to degrade specific proteins essential for cancer cell survival (such as GSPT1). This allows us to kill cancer cells that might be resistant to chemotherapy or traditional ADCs.

ORM-6151: This program (targeting CD33) was acquired by Bristol-Myers Squibb Company (BMS) in 2023. BMS is currently responsible for its clinical development (NCT06419634)

We have validated our platform through high-profile global partnerships:

* Bristol Myers Squibb: Acquired the ORM-6151 program.

* Vertex Pharmaceuticals: Entered a multi-target license and option agreement to use Orum’s TPD² technology for gene editing conditioning agents.

Our lead internal asset is ORM-1153, a DAC that targets CD123 to deliver a GSPT1 degrader. It is being developed for the treatment of hematologic malignancies. We are also advancing a broader preclinical pipeline using our PROTAb platform.

This information is available our About page.

Orum Therapeutics is listed on the KOSDAQ market in South Korea.

• Ticker Symbol: 475830

• Bloomberg Ticker: 475830:KS

Orum is listed on the KOSDAQ market. Shares may be purchased through a registered broker-dealer or an online trading platform of your choice. Major international brokerages and banks often offer access to trade Korean stock. Shares cannot be purchased directly from the company.

• Korean Filings: You can view our official disclosures on the DART (Data Analysis, Retrieval and Transfer System) website run by the Korean Financial Supervisory Service (FSS). These are also available on our ‘Filings’ page under IR

• US Filings: As a KOSDAQ-listed entity, our primary reporting is in South Korea, but major material news is released globally in English via our Investor Relations page and email subscription.
  

Our fiscal year ends on December 31st.

Orum does not distribute dividends on its common stock.

Orum Therapeutics does not currently pay cash dividends. As pre-commercial biotechnology company, we prioritize reinvesting our capital into research and development (R&D) to advance our pipeline and maximizing long-term shareholder value.

For shares held in Korea, the Korea Securities Depository (KSD) acts as the transfer agent. International investors typically hold shares through a global custodian or broker with access to the Korean exchange.

For institutional inquiries, partnership opportunities, or shareholder questions, please refer to our contact page.

You can sign up for email updates through our distribution list here.